Intensity Therapeutics, Inc. (INTS)
INTS Stock Price Chart
Explore Intensity Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze INTS price movements and trends.
INTS Company Profile
Discover essential business fundamentals and corporate details for Intensity Therapeutics, Inc. (INTS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jun 2023
Employees
5.00
CEO
Lewis H. Bender
Description
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
INTS Financial Timeline
Browse a chronological timeline of Intensity Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.06.
Earnings released on 7 Aug 2025
EPS came in at -$0.13 falling short of the estimated -$0.06 by -116.67%.
Earnings released on 13 May 2025
EPS came in at -$0.22 falling short of the estimated -$0.21 by -4.76%.
Earnings released on 13 Mar 2025
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%.
Earnings released on 13 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%.
Earnings released on 8 Aug 2024
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%.
Earnings released on 9 May 2024
EPS came in at -$0.34 .
Earnings released on 14 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%, while revenue for the quarter reached $282.22K .
Earnings released on 13 Nov 2023
EPS came in at -$0.17 falling short of the estimated -$0.09 by -88.89%.
Earnings released on 14 Aug 2023
EPS came in at -$1.43 falling short of the estimated -$0.40 by -257.50%.
Earnings released on 30 Jun 2023
EPS came in at -$0.10 .
Earnings released on 31 Dec 2022
EPS came in at -$0.12 .
Earnings released on 30 Sept 2022
EPS came in at -$0.50 .
Earnings released on 30 Jun 2022
EPS came in at -$0.11 .
Earnings released on 31 Mar 2022
EPS came in at -$0.18 .
Earnings released on 31 Dec 2021
EPS came in at -$0.13 .
Earnings released on 30 Sept 2021
EPS came in at -$0.12 .
Earnings released on 30 Jun 2021
EPS came in at -$0.11 .
Earnings released on 31 Mar 2021
EPS came in at -$0.06 .
Earnings released on 31 Dec 2020
EPS came in at -$0.09 .
INTS Stock Performance
Access detailed INTS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.